ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
海西新藥
147.500
+4.400
3.07%
手動刷新
成交量：
37.62萬
成交額：
5,563.05萬
市值：
116.09億
市盈率：
72.85
高：
151.200
開：
143.200
低：
142.200
收：
143.100
52周最高：
169.300
52周最低：
97.500
股本：
7,870.73萬
香港流通股本：
7,870.73萬
量比：
1.76
換手率：
0.48%
股息：
- -
股息率：
- -
每股收益(LYR):
2.025
淨資產收益率：
28.75%
總資產收益率：
12.62%
市淨率：
18.93
市盈率(LYR):
72.85
市銷率:
21.96
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字：
海西新藥
交易所：
SEHK
成立時間：
2012
員工人數：
164
公司地址：
Floor 3 & 4, Block B,No. 177 Jinda Road,Jianxin Town,Cangshan District,Fuzhou,Fujian Province,China
官網：
http://www.hxpharma.com
郵編：
350028
電話：
86 591 8751 9936
傳真：
- -
簡介：
福建海西新藥創製股份有限公司成立於2012年3月27日。公司是一家處於商業化階段的製藥公司,集研發、生產及銷售能力於一體,具備在研創新藥的管線。公司在中國最大、增長最快的治療領域擁有多元化的產品組合及管線。截至最後實際可行日期,公司已商業化的產品組合主要包括用於消化系統疾病、心血管系統疾病、內分泌系統疾病、神經系統疾病及炎症疾病的仿製藥。根據灼識諮詢的資料,該等治療領域佔2023年中國醫藥銷售總額的25%以上。公司的創新藥管線專註於具有各種適應症的在研藥物,包括一款潛在屬同類首款的在研腫瘤藥物、一款潛在用於治療濕性年齡相關性黃斑變性(wAMD)╱糖尿病性黃斑水腫(DME)╱視網膜靜脈阻塞(RVO)的首款口服藥物及另外兩款處於臨床前階段,用於治療腫瘤及呼吸系統疾病的創新在研藥物。公司所有在研創新藥均由內部以專有方式開發及發展。
董事
名稱
職位
康心汕
董事長，執行董事，戰略委員會主席，薪酬與考核委員會委員，提名委員會主席
Feng Yan
執行董事，戰略委員會委員
Chen Guangming
執行董事
陳樞儀
執行董事，營銷顧問
龔為民
獨立非執行董事，戰略委員會委員，薪酬與考核委員會主席，審核委員會委員
王珊珊
獨立非執行董事，提名委員會委員，審核委員會委員
蒲美婷
獨立非執行董事，薪酬與考核委員會委員，提名委員會委員，審核委員會主席
許冬
非執行董事
王忻琨
非執行董事
陳霞
監事會主席，職工代表監事
吳江
股東代表監事
許麗霞
股東代表監事
股東
名稱
職位
康心汕
總經理
Feng Yan
副總經理
Chen Guangming
副總經理，首席科學官
胡凱
副總經理，總裁助理
張俊環
財務總監，董事會秘書，聯席公司秘書
劉國賢
聯席公司秘書
陳霞
人力資源部經理，運營中心副主任
張明強
研發與全球事務總裁
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02637/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新藥","latestPrice":147.5,"timestamp":1774426110701,"preClose":143.1,"halted":0,"volume":376200,"delay":0,"changeRate":0.03074772886093645,"floatShares":78707270,"shares":78707270,"eps":2.024774,"marketStatus":"未開盤","change":4.4,"latestTime":"03-25 16:08:30","open":143.2,"high":151.2,"low":142.2,"amount":55630535,"amplitude":0.062893,"askPrice":148.9,"askSize":100,"bidPrice":147.5,"bidSize":250,"shortable":0,"etf":0,"ttmEps":2.264,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":143.1,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":1.757123,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"12.62%","roe":"28.75%","lyrEps":2.024774,"volumeRatio":1.757123,"shares":78707270,"dividePrice":0,"high":151.2,"amplitude":0.062893,"preClose":143.1,"low":142.2,"week52Low":97.5,"pbRate":"18.93","psRate":"21.96","week52High":169.3,"institutionHeld":0,"latestPrice":147.5,"committee":0.428571,"eps":2.024774,"divideRate":0,"volume":376200,"delay":0,"ttmEps":2.264,"open":143.2,"prevYearClose":136,"prevWeekClose":137.3,"prevMonthClose":143,"prevQuarterClose":136,"fiveDayClose":143.2,"twentyDayClose":137.8,"sixtyDayClose":132.8,"earningDate":1774800000000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-03-24","current":66.210247,"percent":0.780952,"low":41.43616,"twenty":67.289916,"median":69.721363,"eighty":73.442107,"high":84.764482,"avg":69.771444,"sd":6.270676,"marketCap":11263010337},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-24","current":72.884321,"twenty":67.289916,"median":69.721363,"eighty":73.442107,"marketCap":11263010337}],"updateTime":1774420697577},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":620979011,"yearFounded":2012,"employeeNum":164,"address":"Floor 3 & 4, Block B,No. 177 Jinda Road,Jianxin Town,Cangshan District,Fuzhou,Fujian Province,China","zipCode":"350028","officePhone":"86 591 8751 9936"},"stockCompanyDetail":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0886},{"period":"3month","weight":0.0612},{"period":"6month","weight":0.7072},{"period":"ytd","weight":0.0846}],"compareEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":-0.0645},{"period":"3month","weight":-0.0187},{"period":"6month","weight":-0.0303},{"period":"1year","weight":0.0853},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"HSI","name":"恆生指數"},"description":"福建海西新藥創製股份有限公司成立於2012年3月27日。公司是一家處於商業化階段的製藥公司,集研發、生產及銷售能力於一體,具備在研創新藥的管線。公司在中國最大、增長最快的治療領域擁有多元化的產品組合及管線。截至最後實際可行日期,公司已商業化的產品組合主要包括用於消化系統疾病、心血管系統疾病、內分泌系統疾病、神經系統疾病及炎症疾病的仿製藥。根據灼識諮詢的資料,該等治療領域佔2023年中國醫藥銷售總額的25%以上。公司的創新藥管線專註於具有各種適應症的在研藥物,包括一款潛在屬同類首款的在研腫瘤藥物、一款潛在用於治療濕性年齡相關性黃斑變性(wAMD)╱糖尿病性黃斑水腫(DME)╱視網膜靜脈阻塞(RVO)的首款口服藥物及另外兩款處於臨床前階段,用於治療腫瘤及呼吸系統疾病的創新在研藥物。公司所有在研創新藥均由內部以專有方式開發及發展。","exchange":"SEHK","name":"海西新藥","nameEN":"HAIXI PHARMA"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":{"directors":[{"name":"康心汕","position":"董事長，執行董事，戰略委員會主席，薪酬與考核委員會委員，提名委員會主席"},{"name":"Feng Yan","position":"執行董事，戰略委員會委員"},{"name":"Chen Guangming","position":"執行董事"},{"name":"陳樞儀","position":"執行董事，營銷顧問"},{"name":"龔為民","position":"獨立非執行董事，戰略委員會委員，薪酬與考核委員會主席，審核委員會委員"},{"name":"王珊珊","position":"獨立非執行董事，提名委員會委員，審核委員會委員"},{"name":"蒲美婷","position":"獨立非執行董事，薪酬與考核委員會委員，提名委員會委員，審核委員會主席"},{"name":"許冬","position":"非執行董事"},{"name":"王忻琨","position":"非執行董事"},{"name":"陳霞","position":"監事會主席，職工代表監事"},{"name":"吳江","position":"股東代表監事"},{"name":"許麗霞","position":"股東代表監事"}],"executives":[{"name":"康心汕","position":"總經理"},{"name":"Feng Yan","position":"副總經理"},{"name":"Chen Guangming","position":"副總經理，首席科學官"},{"name":"胡凱","position":"副總經理，總裁助理"},{"name":"張俊環","position":"財務總監，董事會秘書，聯席公司秘書"},{"name":"劉國賢","position":"聯席公司秘書"},{"name":"陳霞","position":"人力資源部經理，運營中心副主任"},{"name":"張明強","position":"研發與全球事務總裁"}]}}}